{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:23:18Z","timestamp":1787674998127,"version":"build-2784847793"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>The management of differentiated thyroid cancer (DTC) has undergone a major paradigm shift over the past decade, with increasing emphasis on treatment de-escalation and avoidance of overtreatment in patients with low-risk disease. The 2015 American Thyroid Association guidelines marked a turning point by discouraging routine postoperative radioiodine (RAI) remnant ablation in low-risk patients, reflecting the excellent prognosis of most papillary thyroid carcinomas and concerns regarding unnecessary therapy-related morbidity. The rising incidence of thyroid cancer, largely due to increased detection of indolent tumors without any rise in mortality, further reinforced a more conservative approach. Although the toxicities of RAI are generally limited, potential long-term effects have also contributed to a reduction in its use. The recent population-based analysis by Weis and colleagues challenges the simplicity of this universal de-escalation strategy. The authors confirmed the lack of survival benefit from RAI in node-negative papillary thyroid carcinoma. On the contrary, they also identified subgroups who appeared to derive a long-term survival advantage from RAI. These findings highlight the biological heterogeneity of DTC and suggest that treatment decisions should extend beyond conventional low-risk classifications, supporting a more individualized and nuanced approach to postoperative RAI use.<\/jats:p>","DOI":"10.1097\/rlu.0000000000006676","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:00:52Z","timestamp":1787673652000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Radioiodine in Low-risk Differentiated Thyroid Cancer"],"prefix":"10.1097","author":[{"given":"Humayun","family":"Bashir","sequence":"first","affiliation":[{"name":"Nuclear Medicine Department, East Kent Hospitals University NHS Foundation Trust, Canterbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamna","family":"Hassan","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Qureshy","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajira","family":"Ilyas","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaf","family":"Mufty","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairah","family":"Razi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1598-6162","authenticated-orcid":false,"given":"Sana Munir","family":"Gill","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"R1-20260825","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"R2-20260825","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.295.18.2164","article-title":"Increasing incidence of thyroid cancer in the United States, 1973\u20132002","volume":"295","author":"Davies","year":"2006","journal-title":"JAMA"},{"key":"R3-20260825","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1200\/JCO.21.01841","article-title":"Association between radioactive iodine treatment for pediatric and young adulthood differentiated thyroid cancer and risk of second primary malignancies","volume":"40","author":"Pasqual","year":"2022","journal-title":"J Clin Oncol"},{"key":"R4-20260825","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1007\/s00259-026-07888-1","article-title":"Long-term relative survival with and without radioiodine in patients with low-risk thyroid cancer: a SEER-based analysis of histologic subtypes and risk factors","volume":"53","author":"Weis","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R5-20260825","first-page":"246","article-title":"Follicular thyroid carcinoma: disease response evaluation and outcome predictors in patients treated with radioiodine","volume":"4","author":"Hassan","year":"2015","journal-title":"Eur Thyroid J"},{"key":"R6-20260825","first-page":"569","article-title":"Can the American Thyroid Association risk of recurrence classification predict radioiodine-refractory disease in differentiated thyroid cancer?","volume":"42","author":"Hassan","year":"2017","journal-title":"Clin Nucl Med"},{"key":"R7-20260825","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3)","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"R8-20260825","first-page":"1912","article-title":"From fixed activities to personalised treatments in molecular radiotherapy: the role of dosimetry","volume":"49","author":"Flux","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R9-20260825","first-page":"784","article-title":"Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL2): a randomised phase 3 equivalence trial","volume":"10","author":"Schlumberger","year":"2022","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006676","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:00:53Z","timestamp":1787673653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006676"}},"subtitle":["Is the Pendulum Moving Again?"],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":9,"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006676","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"2026-07-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}